Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY3015014

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Objective To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
A recent report described a novel mechanism of action for an anti-proprotein convertase subtilisin-kexin type 9 (PCSK9… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Abstract Aims The objective of this study was to evaluate the efficacy, safety, and tolerability of LY3015014 (LY), a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
ABSTRACTPurposeLY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9… Expand
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Is this relevant?
2016
2016
Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast ![Graphic][1] Elevated levels of LDL-cholesterol are… Expand
  • figure 1
  • figure 2
Is this relevant?
2016
2016
This editorial refers to ‘Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type… Expand
  • figure 1
Is this relevant?
2015
2015
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9… Expand
Is this relevant?
2015
2015
Monoclonal antibodies (Mabs) that neutralize proprotein convertase subtilisin-kexin type 9 (PCSK9) cause remarkable LDL… Expand
Is this relevant?